Fertility Preservation Survey: Hemato-Oncologists


Chemotherapy treatment may cause loss of reproductive organ function, premature ovarian failure or the inability to produce mature eggs. Reliably predicting post-treatment ovarian reserve and obtaining post-treatment infertility statistics are difficult.


This survey aims to better understand oncologists’ knowledge of, and attitudes toward fertility preservation for patients with malignancies. Published survey results will help fertility treatment providers and oncologists develop optimized fertility preservation approaches and strategies.


Please take a moment to complete this important survey. A similar survey is being conducted among IVF providers.


Thank you for your collaboration.
Mohamad Mohty, Arnon Nagler, Rafael Duarte


The personal data requested aims only to assure the safety and authenticity of the data submitted. No personal data will be published.


First and last name
Clinic name
1. Country
2. If there is a risk of infertility following treatment for a malignancy, do you inform your patients?

3. Please estimate the percentage of your male patients under the age of 40 who are referred to fertility preservation.

4. Please estimate the percentage of your female patients under the age of 40 who are referred to fertility preservation.

5. Of your young female cancer patients (≤ 40 years old) who underwent treatment that may have adversely affected their future fertility, what is the percentage who actually benefited from a fertility preservation procedure?

6. Is there a lower age limit under which you do not refer to fertility preservation?

7. In your opinion, what should the age limit be for fertility preservation procedures for your female patients?

8. Do you have a specific clinic that you refer to or do the patients choose their own in vitro fertilization clinic?

9. Do you communicate with the reproductive medicine provider when referring the patient?

10. Do you follow up with the patients you referred while they are receiving fertility preservation treatment?

11. In your country, funding for this treatment is covered by:

12. If the disease and situation allow fertility preservation treatment:

13. In your opinion, for most of the patients who are referred to fertility preservation, for how long can oncology treatment can be deferred?

14. Do you think that hormonal treatment for fertility preservation can aggravate the malignant disease?

15. In your country, are there any local/national guidelines on fertility preservation for patients with malignancies?

16. Statement: Fertility preservation is a high priority for me to discuss with female patients newly diagnosed with a malignancy.

17. Statement: In female patients with malignancies, treating the primary malignancy is more important than fertility preservation.

18. Statement: The success rate of fertility preservation in female patients with malignancies is not yet good enough to make fertility preservation an available option.

19. In your opinion, would you like to have international/national guidelines for fertility preservation procedures?